The intrinsic coagulation/kinin-forming cascade: Assembly in plasma and cell surfaces in inflammation

Advances in Immunology

Volumn 66, Issue , 1997, Pages 225-272

  Kaplan, Allen P ^a   Joseph, Kusumam ^a   Shibayama, Yoji ^a,b   Reddigari, Sesha ^a   Ghebrehiwet, Berhane ^a   Silverberg, Michael ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Nippon Zoki Pharmaceutical Co   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BRADYKININ; HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN; KININ; KININOGEN; PREKALLIKREIN;

BLOOD CLOTTING; FIBRINOLYSIS; HUMAN; INFLAMMATION; KALLIKREIN KININ SYSTEM; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 0030885721     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (218)

1. Adam, A. et al. (1985). Human kininogens of low and high molecular mass: Quantification by radioimmunoassay and determination of reference values. Clin. Chern. 31, 423-426.
2. Atkins, P. C., Miragliotta, G., Talbot, S. F., Zweiman, B., and Kaplan, A. P. (1987). Activation of plasma Hageman factor and kallikrein in ongoing allergic reactions in the skin. J. Immunol. 139, 2744-2748.
3. Baglia, F. A., Sinha, D., and Walsh, P. N. (1989). Functional domains in the heavy-chain region of factor XI: A high molecular weight kininogen-binding site and a substrate binding site for factor IX. Blood 74, 244-251.
4. 2-macroglobulin with proteinases. Biochem J 133, 709-724.
5. Baumgarten, C. R., et al. (1985). Influx of kininogens into nasal secretions after antigen challenge of allergic individuals. J. Clin. Invest. 76, 191-197.
6. Baumgarten, C. R., et al. (1986a). Plasma kallikrein during experimentally-induced allergic rhinitis: Role in kinin formation and contribution to TAME esterase activity in nasal secretions. J. Immunol 137, 977-982.
7. Baumgarten, C. R., Nichols, R. C., Naclerio, R. M., and Proud, D. (1986b). Concentrations of glandular kallikrein in human nasal secretions increase during experimentally-induced allergic rhinitis. J. Immunol. 137, 1323-1328.
8. Bernardo, M. M., Day, D. E., Halvorson, H. R., Olson, S. T., and Shore, J. D. (1993a). Surface-independent acceleration of factor XII activation by zinc ions. II. Direct binding and fluorescence studies. J. Biol. Chem. 268, 12477-12483.
9. Bernardo, M. M., Day, D. E., and Olson, S. T. (1993b). Surface-independent acceleration of factor XII activation by zinc ions. I. Kinetic characterization of the metal ion rate enhancement. J. Biol. Chem. 268, 12468.
10. Berrettini, M., et al. (1986). Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma immunoblotting with monoclonal antibodies. Blood 68, 455-462.
11. Berrettini, M., Schleef, R. R., Heeb, M. J., Hopmeier, P., and Griffin, J. H. (1992). Assembly and expression of an intrinsic factor IX activator complex on the surface of cultured human endothelial cells. J. Biol. Chem. 267, 19833-19839.
12. Bock, P. E., and Shore, J. D. (1983). Protein-protein interaction of blood coagulation. Characterization of a fluorescein-labeled human high molecular weight kininogen light chain as aprobe. J. Biol. Chem, 258, 15079-15086.
13. Bock, P. E., Srinivasan, K. R., and Shore, J. D. (1981). Activation of intrinsic blood coagulation by ellagic acid: insoluble ellagic acid metal ion complexes are the activating species. Biochemistry 20, 7258-7271.
14. Bock, P. E., Shore, J. D., Tans, G., and Griffin, J. H. (1985). Protein-protein interactions in contact activation of blood coagulation. Binding of high molecular weight kininogen and the 5-(iodoacetamido) fluorescein-labeled kininogen light chain to prekallikrein, kallikrein, and the separated kallikrein heavy and light chains. J. Biol. Chem. 260, 12434-12443.
15. Bouma, B. N., and Griffin, J. H. (1977). Human blood coagulation factor XI: Purification, properties, and mechanism of activation by factor XII. J. Biol. Chem. 252, 6432-6437.
16. Bouma, B. N., Miles, L. A., Barretta, G., and Griffin, J. H. (1980). Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry 19, 1151-1160.
17. Brunnee, T., et al. Activation of the contact system by glycosaminoglycan derived from mast cell proteoglycan. Submitted for publication.
18. Burman, J. F., Chung, H. I., and Lane, D. A. (1994). Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet 344, 1192.
19. Bush, A. I., et al. (1994). Rapid inducton of Alzheimer A β amyloid formation by zinc. Science, 265, 1464-1467.
20. Cameron, C. L., Fisslthaler, B., Sherman, A., Reddigari, S., and Silverberg, M. (1989). Studies on contact activation: Effects of surfaces and inhibitors. Med. Prog. Tech. 15, 53-62.
21. Castellino, F. J., and Beals, J. M. (1987). The genetic relationships between the kringle domains of human plasminogen, prothrombin, tissue plasminogen activator, urokinase, and coagulation factor XII. J. Mol. Evol. 26, 358-369.
22. Chung, D. W., Fujikawa, K., McMullen, B. A., and Davie, E. W. (1986). Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 25, 2410-2417.
23. Cochrane, C. C., and Revak, S. D. (1980). Dissemination of contact activation in plasma by plasma kallikrein. J. Exp. Med. 152,: 608-619.
24. Cochrane, C. G., Revak, S. D., and Wuepper, K. D. (1973). Activation of Hageman factor in solid and fluid phases. J. Exp. Med. 138, 1564-1583.
25. Colman, R. W. (1969). Activation of plasminogen by plasma kallikrein. Biochem. Biophys. Res. Cornmun. 351, 273.
26. Colman, R. W., and Muller-Esterl, W. (1988). Nomenclature of kininogens. Thromh. Haemost. 60, 340-341.
27. Colman, R. W., et al. (1975). Williams trait: Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor dependent pathways. J. Clin. Invest. 56, 1650-1662.
28. Colman, R. W., Wachtfogel, Y. T., and Kucich, V. (1985). Effects of cleavage of the heavy chain of human plasma kallikrein on its functional properties. Blood 65, 311.
29. Cool, D. E., et al. (1985). Characterization of human blood coagulation factor XII cDNA. J. Biol. Chem. 25, 13666-13676.
30. Creticos, P. S., et al. (1984). Peptide leucotriene release after antigen challenge in patients sensitive to ragweed. N. Engl. J. Med. 310, 1626-1630.
31. Crutchly, D. J., Ryan, J. W., Ryan, U. S., and Fisher, G. H. (1983). Bradykinin induced release of prostacyclin and thromboxanes from bovine pulmonary artery endothelial cells. Biochim. Biophys. Acta 751, 99-107.
32. Cugno, M., Hack, C. E., and de Boer, J. P. (1993). Generation of plasmin during acute attack of hereditary angioedema. J. Lab. Clin. Med. 121, 38.
33. Curd, J. G., Prograis, L. F., Jr., and Cochrane, C. G. (1980). Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J. Exp. Med. 152, 742-747.
34. de Agostini, A., Lijnen, H. R., Pixley, R. A., Colman, R. W., and Schapira, M. (1984). Inactivation of factor XII active fragment in normal plasma. Predominant role of Cl-inhibitor. J Clin Invest 73, 1542-1549.
35. 9-bradykinin. Br. J. Pharmacol. 93, 969-977.
36. 9-bradykinin in vivo and in vitro. Immunopharmacology 17, 187-198.
37. De La Cadena, R. A., et al. (1994). Platelet thrombospondin interactions with human high and low molecular weight kininogens. Thromh. Haemost. 72, 125-131.
38. Dolovich, J., and Little, D. C. (1972). Correlates of skin test reactions to Bacillus subtilis enzyme preparations. J. Allergy Clin. Immunol. 49, 43.
39. Donaldson, V. H. (1968). Mechanisms of activation of Cl esterase in hereditary angioneurotic edema plasma in vitro: The role of Hageman factor, a clot-promoting agent. J. Exp. Med. 127, 411-429.
40. Donaldson, V. H., Glueek, H. I., and Milter, M. A. (1976). Kininogen deficiency in Fitzgerald trait: Role of high molecular weight kininogen in clotting and fibrinolysis. J. Lab. Clin. Med. 89, 327-337.
41. Donaldson, V. H., Rosen, F. S., and Bing, D. H. (1977). Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.). Plasma Trans. Assoc. Am, Physicians 40, 174-183.
42. Dunn, J. T., and Kaplan, A. P. (1982). Formation and structure of human Hageman factor fragments. J. Clin. Invest. 70, 627-631.
43. Dunn, J. T., Silverberg, M., and Kaplan, A. P. (1982). The cleavage and formation of activated Hageman factor by autodigestion and by kallikrein. J. Biol, Chem. 275, 1779-1784.
44. Erdos, E. G., Sloane, G. M. (1962). An enzyme in human plasma that inactivates bradykinin and kallidins. Biochem Pharmacol 11, 585-592.
45. Fields, T., Ghebrehiwet, B., and Kaplan, A. P. (1983). Kinin formation in hereditary angioedema plasma: Evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J. Allergy Clin. Immunol. 72, 54-60.
46. Forbes, C. O., Pensky, J., and Ratnoff, O. D. (1970). Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified Cl inactivator. J. Lab. Clin. Med. 76, 809-815.
47. Fujikawa, K., and McMullen, B. A. (1983). Amino acid sequence of Human b-Factor XIIa. J. Biol, Chem, 258, 10924-10933.
48. Fujikawa, K., Heimark, R. L., Kurachi, K., and Davie, E.W. (1980). Activation of bovine factor XII (Hageman factor) by plasma kallikrein. Biochemistry 19, 1322-1330.
49. Gallin, J. I., and Kaplan, A. P. (1974). Mononuclear cell chemotactic activity of kallikrein and plasminogen activator and its inhibition by C1 INH and a2 macroglobulin. J. Immunol. 113, 1928.
50. Ghebrehiwet, B., Randazzo, B. P., Dunn, J. T., Silverberg, M., and Kaplan, A. P. (1983). Mechanism of activation of the classical pathway of complement by Hageman factor fragment. J. Clin. Invest. 71, 1450-1456.
51. Ghebrehiwet, B., Lim, B.-L., Peerschke, E. I. B., Willis, A. C., and Reid, K. B. M. (1994). Isolation, cDNA cloning and overexpression of a 33-kD cell surface glycoprotein that binds to the globular 'heads' of Clq. J. Exp. Med, 179, 1809-1821.
52. Gigli, I., Mason, J. W., Colman, R. W., and Austen, K. F. (1970). Interaction of plasma kallikrein with the Cl inhibitor. J. Immunol, 104, 574-581.
53. Ginsberg, M., Jaques, B., Cochrane, C. G., and Griffin, J. H. (1980). Urate crystal dependent cleavage of Hageman factor in human plasma and synovial fluid. J. Lab. Clin. Med. 95, 497-506.
54. Goldsmith, G., Saito, H., and Ratnoff, O. D. (1978). The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments. J. Clin. Invest. 12, 54.
55. 1-cysteine proteinase inhibitor. Purification by affinity chromatography, characterization, and isolation of an active fragment. Biochem. J. 221, 445-452.
56. Greengard, J. S., and Griffin, J. H. (1984). Receptor for high molecular kininogen on stimulated washed human platelets. Biochemistry 23, 6863-6869.
57. Griep, M. A., Fujikawa, K., and Nelsestuen, G. L. (1985). Binding and activation properties of human factor XII, prekallikrein and derived peptides with acidic lipid vesicles. Biochemistry 24, 4124-4130.
58. Griffin, J. H. (1978). Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc. Natl. Acad. Sci. USA 75, 1998-2002.
59. Griffin, J. H., and Cochrane, C.G. (1976). Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc. Natl. Acad. Sci. USA 73, 2554-2558.
60. Guimaraes, J. A., Borges, D. R., Prado, E. S., and Prado, J. L. (1973). Kinin converting aminopeptidase from human serum. Biochem. Pharmacol. 22, 403-414.
61. Gurewich, V., Johnstone, M., and Loza, J. P. (1993). Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEBS Lett. 318, 317.
62. Gustafson, E. J., Schutsky, D., Knight, L. C., and Schmaier, A. H. (1986). High molecular weight kininogen binds to unstimulated platelets. J. Clin. Invest. 78, 310-318.
63. Hall, J. M. (1992). Bradykinin receptors: Pharmacological properties and biological roles. Pharmacol. Ther. 56, 131-190.
64. Harpel, P. C. (1974). In Chemistry and Biology of the Kallikrein-Kinin System in Health and Disease (J. J. Pisano and K. F. Austen, Eds.), p. 169. US Government Printing Office, Washington, DC.
65. 2.macroglobulin-kallikrein complexes. J. Biol. Chem. 260, 4257-4263.
66. Hasan, A. A. K., Cines, D. B., Herwald, H., Schmaier, A. H., and Müller-Esterl, W. (1995). Mapping the cell binding site on high molecular weight kininogen domain 5. J. Biol. Chem. 270, 19256-19261.
67. Hauert, J., Nicoloso, G., and Schleuning, W. D. (1989). Plasminogen activators in dextran sulfate-activated euglobulin fraction: A molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis. Blood 73, 994.
68. Heck, L. W., and Kaplan, A. P. (1974). Substrates of Hageman factor: I. Isolation and characterization of human factor XI (PTA) and inhibition of the activated enzyme by a,. antitrypsin. J. Exp. Med. 140, 1615-1630.
69. Henderson, L. M., Figueroa, C. D., and Muller-Esterl, W. (1994). Assembly of contact phase factors on the surface of the human neutrophil membrane. Blood 84, 474.
70. Herwald, H., Hasan, A. A. K., Godovac-Zimmerman, J., Schmaier, A., H., and Muller-Esterl, W. (1965). Identification of an endothelial cell binding site on kininogen domain D3. J. Biol. Chem. 270, 14634-14642.
71. Herwald, H., Dedio, J., Kellner, R., Loos, M., and Müller-Esterl, W. (1996). Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. J. Biol. Chem. 271, 13040-13047.
72. Hess, J. R., Borkowski, J. A., Young, G. S., Strader, C. D., and Ransom, R. W. (1992). Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem. Biophys. Res. Commun. 184, 260-268.
73. Higashiyama, S., et al. (1986). Human high molecular weight kininogen as a thiol protease inhibitor: Presence of the entire inhibition capacity in the native form of heavy chain. Biochemistry 25, 1669-1675.
74. Hirsh, E. F., Nakajima, T., Oshima, G., Erdos, E. G., and Herman, M. (1974). Kinin-system responses in sepsis after trauma in man. J. Surg. Res. 17, 147-153.
75. Hojima, Y., Cochrane, C. G., Wiggins, R. C., Austen, K. F., and Stevens, R. L. (1984). In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood 63, 1453-1459.
76. Hong, S. L. (1980). Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein. Thromb. Res. 18, 787-795.
77. Huisveld, I. A., Haspers, H., and Van Heeswijk, G. M. (1985). Contribution of contact activation factors to urokinase-related fibrinolytic activator in whole plasma. Thrurnb. Haemost. 54, 102.
78. Iatridis, P. G., and Ferguson, J. H. (1962). Active Hageman factor. A plasma lysokinase of the human fibrinolytic system. J. Clin. Invest. 41, 1277.
79. Ikari, N., Sugo, T., Fuji, S., Kato, H., and Iwanaga, S. (1981). The role of bovine high molecular weight kininogen in contact-mediated activation of bovine factor XII: Interaction of HMW kininogen with kaolin and plasma prekallikrein. J. Biochem. 89, 1699-1709.
80. Ishiguro, H., Higashiyama, S., Ohkubo, I., and Sasaki, M. (1987). Mapping of functional domains of human high molecular weight and high molecular weight kininogens using murine monoclonal antibodies. Biochemistry 26, 7021-7029.
81. Jacobsen, S., and Kritz, M. (1967). Some data on two purified kininogens from human plasma. Br. J. Pharmacol 29, 25-36.
82. Jansen, P. M., Pixley, R. A., and Chang, A. C. K. (1994). Inhibition of factor XII in septic-baboons attenuated activation of complement and fibrinolytic systems and reduced the release of neutrophil elastase. Intensive Care Med. 20, S2.
83. Jiang, Y., Muller-Esterl, W., and Schmaier, A. H. (1992). Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. J. Biol Chem. 267, 3712-3717.
84. Johnson, D. A., Salveson, G., Brown, M., and Barrett, A. J. (1987). Rapid isolation of human kininogens. Thromb. Res. 48, 187-193.
85. Jorg, M., and Binder, B. R. (1985). Kinetic analysis of plasminogen activation by purified plasma kallikrein. Thromb. Res. 39, 323.
86. Joseph, K., Ghebrehiwet, B., Peerschke, E. I. B., Reid, B. M., and Kaplan, A. P. (1996). Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: Identity with the receptor that binds to the globular "heads" of Clq (gClqR). Proc. Natl. Acad. Sci. USA 93, 8552-8557.
87. Joseph, K., Bahou, W., and Kaplan, A. P. (1997). Evidence that the zinc-dependent platelet binding for Factor XII and high molecular weight kininogen is GPlb. J. Invest. Med. 45, 267A.
88. Kaplan, A. P., and Austen, K. F. (1970). A prealbumin activator of prekallikrein. J. Immunol. 105,802-811.
89. Kaplan, A. P., and Austen, K. F. (1971). A prealbumin activator of prekallikrein II: Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J. Exp. Med. 133, 696-712.
90. Kaplan, A. P., Kay, A. B., and Austen, K. F. (1972). A prealbumin activator of prekallikrein III. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J. Exp. Med. 135, 81.
91. 2 Macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 77, 2660-2667.
92. Kellermann, J., Lottspeich, F., Henschen, A., and Muller-Esterl, W. (1986). Completion of the primary structure of human high molecular weight kininogen. The amino acid sequence of the entire heavy chain and evidence for its evolution by gene triplication. Eur. J. Biochem. 154, 471-478.
93. Kellermeyer, R. W., and Breckenridge, R. T. (1965). The inflammatory process in acute gouty arthritis. I. Activation of Hageman factor by sodium urate crystals. J. Lab. Clin. Med. 63, 307-315.
94. Kitamura, N., et al. (1985). Structural organization of the human kininogen gene and a model for its evolution. J. Biol. Chem. 260, 8610-8617.
95. Kluft, C. (1976). Occurrence of Cl-inhibitor and other proteinase inhibitors in euglobulin fractions and their influence of fibrinolytic activity. Haenwstasis 5, 136.
96. Kluft, C. (1977). Elimination of inhibition of euglobulin fibrinolysis by use of flufenamate: Involvement of Cl-inactivator. Haenwstasis 6, 351.
97. Kluft, C. (1978). Determination of prekallikrein in human plasma: Optimal conditions for activating prekallikrein. J. Lab. Clin. Med. 91, 83-93.
98. Kluft, C., Wijngaards, G., and Jie, A. (1984). Intrinsic plasma fibrinolysis: Involvement of urokinase-related activity in the factor XII independent plasminogen proactivator pathway. J. Lab. Clin. Med. 103, 408.
99. Kodama, K., Kato, H., and Iwanaga, S. (1985). Isolation of bovine platelet cationic proteins which inhibit the surface-mediated activation of factor XII and prekallikrein. J. Biochem. 97, 139.
100. Kurachi, K., and Davie, E. W. (1977). Activation of human factor XI (plasma thromboplastin antecedent) by factor XIIa (activated Hageman factor). Biochemistry 16, 5831-5839.
101. a. Biochemistry 19, 1330-1338.
102. Lipscomb, M. S., and Walsh, P. N. (1969). Human platelets and factor XI. Localization in platelet membranes of factor Xl-like activity and its functional distinction from that of factor XI. J. Clin. Invest. 63, 1006.
103. Londino, A., and Luparello, F. J. (1984). Factor XII deficiency in a man with gout and angioimmunoblastic Iymphadenopathy. Arch. Intern. Med. 144, 1497-1498.
104. Lottspeich, F., Kellermann, J., Henschen, A., Foertsch, B., and Muller-Esterl, W. (1985). The amino acid sequence of the light chain of human high molecular mass kininogen. Eur. J. Biochem. 152, 307-314.
105. Loza, J. P., Gurewich, V., and Johnstone, M. (1994). Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: A mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb. Haemost. 71, 347.
106. Mandle, R. J., Jr., and Kaplan, A. P. (1977). Hageman factor substrates. II. Human plasma prekallikrein. Mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. J. Biol. Chem. 252, 6097-6104.
107. Mandle, R. J., Jr., and Kaplan, A. P. (1979). Hageman factor dependent fibrinolysis. Generation of fibrinolytic activity by the interaction of human activated factor XI and plasminogen. Blood 54, 850.
108. Mandle, R. J., Jr., Colman, R. W., and Kaplan, A. P. (1976). Identification of prekallikrein and HMW-kininogen as a complex in human plasma. Proc. Natl. Acad. Sci. USA 73,4179-4183.
109. 1 bradykinin receptor. J. Biol. Chem. 269, 21583-21586.
110. Margolis, J. (1958). Activation of plasma by contact with glass: Evidence for a common reaction which releases plasma kinin and initiates coagulation. J. Physiol. 144, 1-22.
111. Mason, J. W., Kleeberg, U. R., Dolan, P., and Colman, R. W. (1970). Plasma kallikrein and Hageman factor in gram-negative bacteremia. Ann. Intern. Med. 73, 545-551.
112. McConnell, D. J. (1972). Inhibitors of kallikrein in human plasma. J. Clin. Invest. 51,1611-1623.
113. McDonagh, J. S., and Ferguson, J. H. (1970). Studies on the participation of Hageman factor in fibrinolysis. Thromb. Haemost. 24, 1.
114. 2 bradykinin receptor. Proc. Natl. Acad. Sci. USA 88, 7724-7728.
115. McMillin, C. R., Saito, H., Ratnoff, O. D., and Walton, A. G. (1974). The secondary structure of human Hageman factor (factor XII) and its alteration by activating agents. J. Clin. Invest. 54, 1312-1322.
116. McMullen, B. A., and Fujikawa, K. (1985). Amino acid sequence of the heavy chain of human a-factor XIIa (activated Hageman factor). J. Biol. Chem. 260, 5328-5341.
117. Meier, H. L., Pierce, J. V., Colman, R. W., and Kaplan, A. P. (1977). Activation and function of human Hageman factor. The role of high molecular kininogen and prekallikrein. J. Clin. Invest. 60, 18-31.
118. Meijers, J. C., Vlooswijk, R. A. A., and Bouma, B. N. (1988). Inhibition of human blood coagulation factor XIa by Cl Inhibitor. Biochemistry 27, 959-963.
119. Meloni, F. J., and Schmaier, A. H. (1991). Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. J. Biol. Chem. 266, 6786-6794.
120. Meloni, F. J., Gustafson, E. J., and Schmaier, A. H. (1992). High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage. Blood 79, 1233-1244.
121. Miles, L. A., Rothschild, Z., and Griffin, J. H. (1981). Dextran sulfate stimulated fibrinolytic activity in whole human plasma. Dependence on the contact activation system and a urokinase-related antigen. Thromb. Haemost. 46, 211.
122. Miles, L. A., Greengard, J. S., and Griffin, J. H. (1983a). A comparison of the abilities of plasma kallikrein, factor XIIa, factor XIa, and urokinase to activate plasminogen. Thromb. Res. 29, 407.
123. Miles, L. A., Rothschild, Z., and Griffin, J. H. (1983b). Dextran sulfate dependent fibrinolysis in whole human plasma. J. Lab. Clin. Med. 101, 214.
124. Moorman, R. M., Reynolds, D. S., and Comunale, M. E. (1993). Management of cardiopulmonary bypass in a patient with congenital factor XII deficiency. J. Cardiothorac. Vasc. Anesth. 7, 452.
125. Mori, K., and Nagasawa, S. (1981). Studies on human high molecular weight (HMW) kininogen. II. Structural change in HMW kininogen by the action of human plasma kallikrein. J. Biochem. 89, 1465-1473.
126. Mori, K., Sakamoto, W., and Nagasawa, S. (1981). Studies on human high molecular weight (HMW) kininogen III. Cleavage of HMW kininogen by the action human salivary kallikrein. J. Biochem. 90, 503-509.
127. Morrison, D. C., and Cochrane, C. G. (1974). Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J. Exp. Med. 140, 797-811.
128. 2-cysteine protease inhibitors. Evidence from immunological, enzymological, and sequence data. FEBS Lett. 182, 310-314.
129. Miiller-Esterl, W., Rauth, G., Lottspeich, F., Kellermann, J., and Henschen, A. (1985b). Limited proteolysis of human low-molecular mass kininogen by tissue kallikrein. Isolation and characterization of the heavy and light chains. Eur. J. Biochem. 149, 15-22.
130. Nagase, H., Cawston, J. E., DeSilva, M., and Barrett, A. J. (1982). Identification of plasma kallikrein as an activator of latent collagenase in rheumatoid synovial fluid. Biochim. Biophys. Acta 707, 133-142.
131. Nishikawa, K., Kuna, P., Calcaterra, E., Kaplan, A. P., and Reddigari, S. R. (1992). Generation of the vasoactive peptide bradykinin from human high molecular weight kininogen bound to human umbilical vein endothelial cells. Blood 80, 1980-1988.
132. O'Donnell, T. F., Clowes, G. H. J., Talamo, R. C., and Colman, R. W. (1976). Kinin activation in the blood of patients with sepsis. Surg. Gynecol. Obstet. 143, 539-545.
133. Ogston, D., Ogston, L. M., Ratnoff, O. D., and Forbes, C. O. (1967). Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform. The participation of Hageman factor and additional cofactors. J. Clin. Invest. 48, 1786.
134. Ogston, D., Bennett, N. B., and Ogston, C. M. (1971). The assay of a plasma component necessary for the generation of a plasminogen activator in the presence of Hageman factor (Hageman factor cofactor). Br. J. Haematol. 20, 209.
135. Ohkubo, I., Kurachi, K., Takasawa, T., Shiokawa, H., and Sasaki, M. (1984). Isolation of cDNA for alpha-2-thiol protease inhibitor and its identity with low molecular weight kininogen. Biochemistry 23, 3891.
136. Pedersen, O. D., Munkvad, S., and Gram, J. (1993). Depression of factor XII-dependent fibrinolytic activity in survivors of acute myocardial infarction at risk of reinfarction. Eur. Heart J. 1993.
137. Pettinger, M. A., and Young, R. (1970). Endotoxin-induced kinin (bradykinin) formation: Activation of Hageman factor and plasma kallikrein in human plasma. Life Sci. 9,313-322.
138. Pixley, R. A., Schapira, M., and Colman, R. W. (1985). The regulation of human factor XII by plasma proteinase inhibitors. J. Biol Chem. 260, 1723-1729.
139. Pixley, R. A., Stumpo, L. G., Birkmeyer, K., Silver, L., and Colman, R. W. (1987). A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation. J. Biol. Chem. 262, 10140-10145.
140. Pixley, R. A., et al. (1992). Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am. J. Pathol. 140, 897-906.
141. Pixley, R.A., et al. (1993). The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal baterimia. In vivo use of a monoclonal anti Factor XII antibody to block contact activation in baboons. J. Clin. Invest. 92, 61-68.
142. Proctor, R. R., and Rapaport, S. J. (1961). The partial thromboplastin time with kaolin: A simple screening test for first stage clotting deficiencies. Am. J. Clin. Pathol. 35, 212-219.
143. Proud, D., Pierce, J. V., and Pisano, J. J. (1980). Radioimmunoassay of human high molecular weight kininogen in normal and deficient plasma. J. Lab. Clin. Med. 95, 563-574.
144. Proud, D., et al. (1983). Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J. Clin. Invest. 72, 1678-1685.
145. Puri, R. N., Zhou, F., Hu, C.-J., and Colman, R. W. (1991). High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin the platelets. Blood 77, 500-507.
146. Que, B. G., and Davie, E. W. (1986). Characterization of a cDNA coding for human factor XII (Hageman factor). Biochemistry 8, 1525-1528.
147. Ratnoff, O. D., and Crum, J. D. (1964). Activation of Hageman factor by solutions of ellagic acid. J. Lab. Clin. Med. 63, 359-377.
148. Ratnoff, O. D., and Saito, H. (1979). Amidolytic properties of single chain activated Hageman factor. Proc. Natl. Acad. Sci. USA 76, 1461-1463.
149. Reddigari, S., and Kaplan, A. P. (1989a). Monoclonal antibody to human high molecular weight kininogen recognizes its prekallikrein binding site and inhibits its coagulant activity. Blood 74, 695-702.
150. Reddigari, S., and Kaplan, A. P. (1989b). Quantification of human high molecular weight kininogen by immunoblotting with a monoclonal anti-light chain antibody. J. Immunol. Methods 119, 19-25.
151. Reddigari, S. R., and Kaplan, A. P. (1988). Cleavage of high molecular weight kininogen by purified kallikreins and upon contact activation of plasma. Blood 71, 1334-1340.
152. Reddigari, S. R., et al. (1993a). Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains. Blood 81, 1306-1311.
153. Reddigari, S. R., Shibayama, Y., Brunnee, T., and Kaplan, A. P. (1993b). Human Hageman factor (FXII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J. Biol. Chem. 268, 11982-11987.
154. Regoli, D., and Barabe, J. (1980). Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32, 1-46.
155. Revak, S. D., Cochrane, C. G., Johnston, A. R., and Hugli, T. E. (1974). Structural changes accompanying enzymatic activation of human Hageman factor. J. Clin. Invest. 54, 619-627.
156. Revak, S. D., Cochrane, C. G., and Griffin, J. H. (1977). The binding and cleavage characteristics of human Hageman factor during contact activation: A comparison of normal plasma with plasma deficient in factor XI, prekallikrein or high molecular weight kininogen. J. Clin. Invest. 58, 1167-1175.
157. Robinson, J. A., Klodynicky, M. L., Loeb, H. S., Recic, M. R., and Gunnar, R. M. (1975). Endotoxin, prekallikrein, complement, and systemic vascular resistances. Sequential measurement in man. Am, J. Med. 59, 61-67.
158. Roeise, O., Bouma, B. N., Stadaas, J. O., and Aasen, A. O. (1988). Dose dependence of endotoxin-induced activation of the plasma contact system: An in vitro study. Circ. Shock 26, 419-430.
159. Rosing, J., Tans, G., and Griffin, J. H. (1985). Surface-dependent activation of human factor XII by kallikrein, and its light chain. Eur. J. Biochem. 151, 531-538.
160. Saito, H., Ratnoff, O. D., and Donaldson, V. H. (1974). Defective activation of clotting, fibrinolytic and permeability-enhancing systems in human Fletcher trait. Circ. Res. 34, 641-651.
161. Schapira, M., Despland, E., Scott, C. F., Boxer, L. A., and Colman, R. W. (1982a). Purified human plasma kallikrein aggregates human blood neutrophils. J. Clin. Invest. 69, 1199.
162. Schapira, M., Scott, C. F., and Colman, R. W. (1982b). Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J. Clin. Invest. 69, 462-468.
163. Schiffman, S., Mannhalter, C., and Tynerk, D. (1980). Human high molecular weight kininogen. Effects of cleavage by kallikrein on protein structure and procoagulant activity. J. Biol. Chem. 255, 6433-6438.
164. Schmaier, A. H., et al. (1983). High molecular weight kininogen: A secreted platelet protein. J. Clin. Invest. 71, 1477.
165. Schmaier, A. H., et al. (1984). The effects of high molecular weight kininogen on surface-adsorbed fibrinogen. Thromb. Res. 33, 51-57.
166. Schmaier, A. H., et al. (1986a). High molecular weight kininogen is an inhibitor of platelet calpain. J. Clin. Invest. 77, 1565-1573.
167. Schmaier, A. H., Smith, P. M., Pardon, A. D., White, J. G., and Colman, R. W. (1986b). High molecular weight kininogen: Localization in the unstimulated and activated platelet and activation by a platelet calpain(s). Blood 67, 119.
168. Schmaier, A. H., Kuo, A., Lundberg, D., Murray, S., and Cines, D. B. (1988). The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J. Biol. Chem. 263, 16327-16333.
169. Schmidt, V., Vitale, E., and Bahou, W. (1996). Genomic cloning and characterization of the human thrombin receptor gene: Structural similarity to the proteinase activated receptor-2 (PAR-2) gene. J. Biol. Chem. 271, 9307.
170. Schreiber, A. D., Kaplan, A. P., and Austen, K. F. (1973). Inhibition by CI INH of Hageman factor fragment activation of coagulation, fibrinolysis, and kinin generation. J. Clin. Invest. 52, 1402-1409.
171. 1-protease inhibitor and protective effect of high molecular weight kininogen. J. Clin. Invest. 69, 844-852.
172. Scully, M. F., Weerasinghe, K., and Kakhar, V. V. (1980). Inhibition of contact activation by platelet factor 4. Thromb. Res. 20, 461.
173. Sheikh, I. A., and Kaplan, A. P. (1986a). Studies of the digestion of bradykinin, lysylbradykinin and des-arg9 bradykinin by angiotensin converting enzyme. Biochem. Pharmacol. 35, 1951-1956.
174. Sheikh, I. A., and Kaplan, A. P. (1986b). Studies of the digestion of bradykinin, lysylbradykinin and kinin degradation products by carboxypeptidases A, B and N. Biochem. Pharmacol. 35, 1957-1963.
175. Sheikh, I. A., and Kaplan, A. P. (1989). The mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum: The role of carboxy-peptidase, angiotensin converting enzyme, and determination of final degradation products. Biochem. Pharmacol. 38, 993-1000.
176. Shibayama, Y., Brunnee, T., and Kaplan, A. P. (1994). Activation of human Hageman factor (Factor XII) in the presence of zinc and phosphate ions. J. Med. Biol. Res. 27, 1817.
177. Shibayama, Y., Konishi, J.-E., Nakamura, T., Suehiro, S., and Kaplan, A. P. (1997). Activation of the plasma kinin forming cascade by aggregated Alzheimer A β amyloid protein. American Soc. Clin. Invest., in press. [abstract]
178. Silverberg, M., and Diehl, S. V. (1987a). The activation of the contact system of human plasma by polysaccharide sulfates. Ann. N.Y. Acad. Sci. 516, 268-279.
179. r heparin and dextran sulphate. Biochem. J. 248, 715-720.
180. Silverberg, M., and Kaplan, A. P. (1982). Enzymatic activities of activated and zymogen forms of human Hageman factor (factor XII). Blood 60, 64-70.
181. Silverberg, M., Dunn, J. T., Garen, L., and Kaplan, A. P. (1980a). Autoactivation of human Hageman factor: Demonstration utilizing a synthetic substrate. J. Biol. Chem. 255, 7281-7286.
182. Silverberg, M., Nicoll, J. E., and Kaplan, A. P. (1980b). The mechanism by which the light chain of cleaved HMW-kininogen augments the activation of prekallikrein, factor XI, and Hageman factor. Thromb. Res. 20, 173-189.
183. Sinha, D., Seaman, F. S., and Koshy, A. (1984). Blood coagulation factor XIa binds specifically to a site on activated human platelets distinct from that for factor XI. J. Clin. Invest. 73, 1550.
184. Smith, A. M. J., Webb, C., and Holford, J. (1995). Signal transduction pathways for B1 and B2 bradykinin receptors in bovine pulmonary artery endothelial cells. Mol. Pharmacol. 47, 525.
185. Smith, D., Gilbert, M., and Owen, W. G. (1985). Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 66, 835-839.
186. Soter, N. A., Austen, K. F., and Gigli, I. (1975). Inhibition by e-aminocaproic acid of the activation of the first component of the complement system. J. Immunol. 114, 928-932.
187. Stead, N., Kaplan, A. P., and Rosenberg, R. D. (1976). Inhibition of activated factor XII by antithrombin-heparin cofactor. J. Biol. Chem. 251, 6481-6488.
188. Stewart, J. M., et al. (1996). A new generation of bradykinin antagonists. Immunopharmacology 33, 51-60.
189. Strang, C. J., et al. (1988). Angioedema induced by a peptide derived from complement component C2. J. Exp. Med. 168, 1685-1698.
190. Tait, J., and Fujikawa, K. (1986). Identification of the binding site plasma prekallikrein in human high molecular weight kininogen. J. Biol. Chem. 261, 15396-15401.
191. Tait, J. F., and Fujikawa, K. (1987). Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J. Biol. Chem. 262, 11651-11656.
192. Takagaki, Y., Kitamura, N., and Nakanishi, S. (1985). Cloning and sequence analysis of cDNAs for high molecular weight and low molecular weight prekininogens. J. Biol. Chem. 260, 8601-8609.
193. Tankersley, D. L., and Finlayson, J. S. (1984). Kinetics of activation and autoactivation of human factor XII. Biochemistry 23, 273-279.
194. Tankersley, D. L., Fournel, M. A., and Schroeder, D. D. (1980). Kinetics of activation of prekallikrein by prekallikrein activator. Biochemistry 19, 3121.
195. Tans, G., and Griffin, J. H. (1982). Properties of sulfatides in factor XII dependent contact activation. Blood 59, 69-75.
196. Tans, G., Rosing, J., and Griffin, J. D. (1983). Snlfatide dependent autoactivation of human blood coagulation factor XII (Hageman factor). J. Biol. Chem. 258, 8215-8222.
197. Thompson, R. E., Mandle, R. J., Jr., and Kaplan, A. P. (1977). Association of factor XI and high molecular weight kininogen in human plasma. J. Clin. Invest. 60, 1376-1380.
198. Thompson, R. E., Mandle, R. J., and Kaplan, A. P. (1978). Characterization of human high molecular weight kininogen. Procoagulant activity associated with the light chain of kinin-free high molecular weight kininogen. J. Exp. Med. 147, 488-499.
199. Thompson, R. E., Mandle, R. J., and Kaplan, A. P. (1979). Studies of the binding of prekallikrein and factor XI to high molecular weight kininogen and its light chain. Proc. Natl. Acad. Sci. USA 79, 4862-4866.
200. Travis, J., and Salvesen, G. S. (1983). Human plasma proteinase inhibitors. Annu. Rev. Biochem. 52, 655-709.
201. Tuszynski, G. P., Bevacona, S. J., Schmaier, A. H., Colman, R. W., and Walsh, P. N. (1982). Factor XI antigen and activity in human platelets. Blood 59, 1148.
202. van der Graaf, F., Koedam, J. A., and Bouma, B. N. (1983). Inactivation of kallikrein in human plasma. J. Clin. Invest. 71, 149-158.
203. Van Iwaarden, F., deGroot, P. G., and Bouma, B. N. (1988). The binding of high molecular weight kininogen to cultured human endothelial cells. J. Biol. Chem. 263, 4698-4703.
204. Vu, T. K. H., Hung, D. T., Wheaton, V. I., and Coughlin, S. H. (1991). Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64, 1057-1064.
205. Wachtfogel, Y. T., et al. (1983). Human plasma kallikrein releases neutrophil elastase activity during blood coagulation. J. Clin. Invest. 22, 1672.
206. Wachtfogel, Y. T., Pixley, R. A., and Kucich, U. (1986). Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 67, 1731.
207. Wachtfogel, Y. T., et al. (1994). High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). J. Biol. Chem. 269, 19307-19312.
208. Walsh, P. N. (1962). The effects of collagen and kaolin on the intrinsic coagulant activity of platelets. Evidence for an alternative pathway in intrinsic coagulation not requiring factor XII. Br. J. Naematol. 22, 393.
209. Walsh, P. N., and Griffin, J. H. (1981). Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood 57, 106-118.
210. Wang, W., Hendriks, D. K., and Scharpé, S. S. (1994). Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J. Biol. Chem. 269, 15937-15944.
211. Warn-Cramer, B. J., and Bajaj, S. P. (1985). Stoichiometry of binding of high molecular weight kininogen to factor XI/XIa. Biochem. Biophys. Res. Commun. 133, 417-422.
212. Weiss, A. S., Gallin, J. I., and Kaplan, A. P. (1974). Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J. Clin. Invest. 53, 622-633.
213. Weiss, R., Silverberg, M., and Kaplan, A. P. (1986). The effect of CI inhibitor upon Hageman factor autoactivation. Blood 68, 239-243.
214. Wiggins, R. C., Bouma, B. N., Cochrane, C. C., and Griffin, J. H. (1977). Role of high molecular weight kininogen in surface-binding and activation of coagulation factor XIa and prekallikrein. Proc. Natl. Acad. Sci. USA 77, 4636-4640.
215. Wiggins, R. C., Giglas, P. C., and Henson, P. M. (1981). Chemotactic activating generated from the fifth component of complement by plasma kallikrein of the rabbit. J. Exp. Med. 153, 1391.
216. Wuepper, K. D. (1973). Prekallikrein deficiency in man. J. Exp. Med. 138, 1345-1355.
217. Wuepper, K. D., Miller, D. R., and LaCombe, M. J. (1975). Flaujeac trait. Deficiency of human plasma kininogen. J. Clin. Invest. 56, 1663-1672.
218. Wuillemin, W. A., Minnema, M., and Meijers, J. C. (1995). Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: Major role for C1-inhibitor. Blood 85, 1517.